AstraZeneca Pharma India is trading at RS. 8026.05, up by 107.10 points or 1.35% from its previous close of RS. 7918.95 on the BSE.

The stock opened at RS. 7870.45 and hit a high of RS. 8089.00 and a low of RS. 7870.00 during the session. So far, 393 shares have been traded on the counter.

Classified under BSE group 'A', the stock with a face value of RS. 2 had touched a 52-week high of RS. 9199.00 on April 24, 2025, and a 52-week low of RS. 5415.55 on June 4, 2024. In the past week, the stock's high and low stood at RS. 8107.40 and RS. 7821.00, respectively. The company's current market capitalization is RS. 19947.50 crore.

Promoters hold 75.00% of the company’s shares, while institutions and non-institutions hold 7.53% and 17.48% respectively.

The company has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import Benralizumab 30 mg/ml Solution for Injection (brand name: Fasenra) for an additional indication.

This approval allows Benralizumab to be marketed as an add-on treatment for adult patients suffering from relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), subject to any further statutory approvals.

AstraZeneca Pharma India is a global biopharmaceutical firm engaged in the discovery, development, and commercialization of medicines across key areas such as cardiovascular/metabolic diseases, cancer, respiratory, inflammatory, and autoimmune conditions. The company operates through two key segments: Healthcare and Clinical Trial.